Compare PLSE & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | ATEC |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2015 | 2006 |
| Metric | PLSE | ATEC |
|---|---|---|
| Price | $25.49 | $7.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $22.00 | $22.00 |
| AVG Volume (30 Days) | 348.7K | ★ 4.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.04 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $101,739,000.00 |
| Revenue This Year | $840.00 | $18.97 |
| Revenue Next Year | $287.54 | $16.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.56 | $6.82 |
| 52 Week High | $27.98 | $23.29 |
| Indicator | PLSE | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 40.42 |
| Support Level | $17.58 | $6.82 |
| Resistance Level | $27.14 | $16.58 |
| Average True Range (ATR) | 1.79 | 0.43 |
| MACD | 0.28 | 0.14 |
| Stochastic Oscillator | 70.28 | 74.69 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.